GO
Loading...

Allergan Inc

More

  • Final Glance: Medical Devices companies Thursday, 11 Dec 2014 | 6:02 PM ET

    Allergan rose $1.04 or. 5 percent, to $211.14. Baxter International Inc. rose$. 35 or. 5 percent, to $73.11. Boston Scientific Corp. rose$. 29 or 2.3 percent, to $12.89.

  • Midday Glance: Medical Devices companies Thursday, 11 Dec 2014 | 1:19 PM ET

    Allergan rose $1.01 or. 5 percent, to $211.11. Baxter International Inc. rose$. 48 or. 7 percent, to $73.24. Boston Scientific Corp. rose$. 24 or 1.9 percent, to $12.84.

  • Early Glance: Medical Devices companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Allergan rose $1.18 or. 6 percent, to $211.29. Baxter International Inc. rose$. 59 or. 8 percent, to $73.35. Boston Scientific Corp. rose$. 09 or. 7 percent, to $12.69.

  • It spent $5.7 billion for the rights to some injectable wrinkle treatments of Valeant Pharmaceuticals and for L'Oreal's share of a dermatology joint venture the two operated. Nestle is also spending about $350 million on dermatology research and development this year, said Humberto Antunes, chief executive of Nestle Skin Care. The first of the new research...

  • Final Glance: Medical Devices companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Allergan fell $2.30 or 1.1 percent, to $210.10. Baxter International Inc. fell $1.03 or 1.4 percent, to $72.76. Boston Scientific Corp. fell$. 44 or 3.4 percent, to $12.60.

  • Midday Glance: Medical Devices companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Allergan fell $1.33 or. 6 percent, to $211.07. Baxter International Inc. fell$. 39 or. 5 percent, to $73.40. Boston Scientific Corp. fell$. 22 or 1.6 percent, to $12.83.

  • Early Glance: Medical Devices companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Allergan fell$. 68 or. 3 percent, to $211.72. Baxter International Inc. fell$. 08 or. 1 percent, to $73.71. Boston Scientific Corp. fell$. 14 or 1.1 percent, to $12.90.

  • Final Glance: Medical Devices companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Allergan fell$. 16 or. 1 percent, to $212.40. Baxter International Inc. fell$. 33 or. 4 percent, to $73.79. Boston Scientific Corp. rose$. 10 or. 8 percent, to $13.04.

  • Midday Glance: Medical Devices companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Allergan fell$. 94 or. 4 percent, to $211.62. Baxter International Inc. fell$. 74 or 1.0 percent, to $73.38. Boston Scientific Corp. rose$. 05 or. 4 percent, to $12.99.

  • Early Glance: Medical Devices companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Allergan fell $1.07 or. 5 percent, to $211.49. Baxter International Inc. fell$. 61 or. 8 percent, to $73.51. Boston Scientific Corp. fell$. 05 or. 4 percent, to $12.89.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Final Glance: Medical Devices companies Monday, 8 Dec 2014 | 6:02 PM ET

    Allergan fell$. 79 or. 4 percent, to $212.56. Baxter International Inc. fell$. 10 or. 1 percent, to $74.12. Boston Scientific Corp. rose$. 03 or. 2 percent, to $12.94.

  • Midday Glance: Medical Devices companies Monday, 8 Dec 2014 | 1:20 PM ET

    Allergan fell$. 15 or. 1 percent, to $213.20. Baxter International Inc. fell$. 01 or percent, to $74.21. Medtronic fell$. 03 or percent, to $75.01.

  • Early Glance: Medical Devices companies Monday, 8 Dec 2014 | 10:22 AM ET

    Allergan rose$. 39 or. 2 percent, to $213.74. Baxter International Inc. rose$. 13 or. 2 percent, to $74.35. Boston Scientific Corp. rose$. 01 or. 1 percent, to $12.92.

  • BOSTON, Nov 26- Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.. One week after Allergan agreed to sell itself to rival Actavis Plc., Ackman wrote in his quarterly investment letter that his Pershing Square Capital Management, the Botox-maker's biggest...

  • *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures pointed to a higher open on Monday, indicating that major indexes would move further into record territory on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday,...

  • US STOCKS-Futures rise, boosted by merger activity Monday, 24 Nov 2014 | 8:14 AM ET

    *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures rose on Monday, indicating that major indexes would move further into record territory, on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday, with the Dow and S&P...

  • Goldman Sachs Group Inc retained its No. 1 position as M&A adviser with deals worth $877 billion, followed by JPMorgan Chase& Co with $651 billion and Citigroup Inc with $633 billion. The $66.4 billion bid for Allergan Inc by Actavis PLC this week more than doubled the total value of deals in the healthcare sector to $364 billion. Halliburton Co's plans to buy...

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.